BioSpace News Archive

Combined Therapeutics Inc. (CTx) today announced its participation in the upcoming World Vaccine Congress 2023, taking place in Washington, D.C., April 4-6, where it will present its cutting-edge mRNA-based vaccine technology MOPCTx in a poster presentation and oral communication.

Bigfoot Biomedical (Bigfoot), a leader in developing intelligent connected injection support systems, today announced the acquisition of a reinforcement learning algorithm for the titration of insulin settings developed at McGill University.

Lineage Cell Therapeutics, Inc. and the Christopher & Dana Reeve Foundation are proud to present the 1st Annual Spinal Cord Injury Investor Symposium, a forum to discuss the recent innovation, advancements, and challenges in the treatment of spinal cord injury.

Psilera is proud to achieve a landmark preclinical milestone with 100% success.

ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“ImmunoPrecise” or “IPA” or the “Company”) an AI-driven biotherapeutic research and technology company today announced a research collaboration and exclusive option license agreement with Xyphos Biosciences, Inc. (a wholly owned subsidiary of Astellas Pharma Inc., “Astellas”).

Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced financial results for the fourth quarter and full year ended December 31, 2022 and provided a business update.

Allogene Therapeutics, Inc., a clinical-stage biotechnology company pioneering the development of allogeneic CAR T products for cancer, published its 2022 annual ESG report.

Dyadic International, Inc. announced that its Chief Executive Officer, Mark Emalfarb will be presenting at the upcoming World Vaccine Congress in Washington, D.C.

Acasti Pharma Inc. announced that Mr. Jean-Marie Canan had tendered his resignation from the Board of Directors of the Company, such resignation to take effect immediately.

Cadrenal Therapeutics, Inc., (Nasdaq: CVKD) a biopharmaceutical company focused on developing tecarfarin, a late-stage novel cardiorenal therapy with orphan drug and Fast Track designations, today provided a corporate update in connection with the filing of its Annual Report on Form 10-K for the year ended December 31, 2022.